Cover Image
Market Research Report

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

Published by GBI Research Product code 249116
Published Content info 97 Pages
Immediate Delivery Available
Price
Back to Top
Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities
Published: August 22, 2012 Content info: 97 Pages
Description

Summary

GBI Research, leading business intelligence provider has released its latest research report, entitled "Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities". The report provides insights into the substance abuse therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major substance abuse indications, which include nicotine addiction, alcohol dependence and opioid and cocaine abuse, as well as insights into the substance abuse therapeutics R&D pipeline. In addition, it analyzes the competitive landscape through the analysis of M&A and licensing deals.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the substance abuse therapeutics market in the top seven markets was valued at $8.8 billion in 2011, increasing at a CAGR of 4.9% during the review period 2004-2011. The market is projected to witness moderate growth of 5.3% during the 2011-2018 forecast period to reach $12.7 billion. The moderate growth of the market can be attributed to the presence of generics in the market, low compliance with therapy due to the nature of addiction and the lack of innovative products in the pipeline. However, indications such as cocaine addiction, which currently have no approved products, are expected to see entries to the market and high-priced products such as Champix for smoking cessation will not see patent expiry in the forecast period.

Scope

  • Data and analysis on the substance abuse therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the substance abuse therapeutics market from 2004-2011 with forecasts to 2018.
  • Market data on the therapeutic landscape, which covers nicotine addiction, alcohol dependence and opioid and cocaine abuse. This includes market size, annual cost of therapy, treatment flow algorithm.
  • Key drivers and restraints that have had a significant impact on the market and on each indication.
  • The competitive landscape of the global substance abuse therapeutics market, which includes companies such as Pfizer, GSK, Forest Laboratories, Alkermes and Reckitt Benckiser.
  • Key M&A activities and licensing agreements that took place from 2007 to 2011 in the global substance abuse therapeutics market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and substance abuse therapeutics market segments poised for strong growth.
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the global substance abuse therapeutics market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling therapeutics of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Executive Summary

Anti-Smoking Legislation Vital for Nicotine Addiction to go up in Smoke, says Report

Anti-smoking legislation and structured support from healthcare providers is essential to achieve widespread smoking cessation, claims a new report by healthcare experts GBI Research.

The new report* argues that the effectiveness of current pharmaceutical treatments depends as much on enforced legislation, such as smoking bans, and support from healthcare providers as an individual's willingness to quit.

According to the World Health Organization (WHO), up to half of all 'lifelong' tobacco users will die from a tobacco-related disease, while the five million deaths that occur as a result of smoking every year outnumber the collective lives lost to HIV/AIDS, malaria and tuberculosis. Nicotine addiction therefore represents a serious public health risk and must be met with effective cessation therapies.

GBI Research claims that the prevalent population for nicotine addiction stood at 136.7 million in 2011, while the 'diagnosed' population, defined as those going to visit a physician concerning smoking cessation, was only 40 million. Furthermore, GlaxoSmithKline claims that while 70% of smokers want to quit less than 5% actually do, indicating a massive opportunity for companies willing to enter the market.

Popular Nicotine Replacement Therapies (NRTs) are conveniently available over-the-counter and account for 75% of all smoking cessation therapies sold worldwide, with patches, gum, lozenges, sprays and inhalers available to deliver doses of nicotine and reduce the effects of withdrawal.

FDA-approved prescription medications for smoking cessation include the nicotine receptor agonist Chantix (varenicline) and the antidepressant Buproprion (marketed as Zyban, Wellbutrin, Voxra, Budeprion, and Aplenzin). However, while these drugs act to alleviate nicotine withdrawal symptoms and the severity of nicotine cravings, both carry associated risks of suicidal tendencies, with Chantix having been forced to carry a 'black box' warning since 2008.

The increasing emergence of smokeless electronic 'e-cigarette' products have split opinion as effective treatments as, while e-cigarettes are often marketed as anti-smoking treatments, they are often sponsored by large tobacco companies and arguably serve to keep smokers addicted. Furthermore, the 'e-cigarette' market is currently unregulated, while low-grade nicotine is often used, which may have unpleasant and possibly dangerous side-effects.

The report states that increasing numbers of patients seeking treatment are being supported by healthcare campaigns around the world. Government efforts are evident in the UK, where the NHS Stop Smoking service enabled over half a million patients to access smoking cessation therapy during April 2011-December 2011 alone.

The report goes on to indicate that future revenues will be made from smoking cessation therapies in countries where legislation and healthcare campaigns are not yet present. South East Asia represents a huge potential market for the next 15 years, as a very high smoking prevalence rate is contrasted with the lack of an established market for NRT or anti-smoking products. GBI Research healthcare analyst, Amy Baker, said: "This market is as yet largely untapped because of cultural attitudes to smoking and a lack of public health efforts; but, should any companies in the future crack the Asian markets, it will offer a massive opportunity."

The global nicotine addiction therapeutics market was estimated at $4.5 billion in 2011, indicating a CAGR of 3.1% between 2004 and 2011. The value is expected to reach $6.2 billion in 2018, following growth at a CAGR of 4.5% between 2011 and 2018.

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

The report provides insights into the substance abuse therapeutics market, including market forecasts up to 2018, and an in-depth analysis of the major substance abuse indications, which include nicotine addiction, alcohol dependence and opioid and cocaine abuse. It additionally gives insights into the substance abuse therapeutics R&D pipeline, and analyzes the competitive landscape through the analysis of M&A and licensing deals.

The report is built using data and information sourced from proprietary databases, primary and secondary secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Substance Abuse Therapeutics Market to 2018-Introduction

  • 2.1. Overview

3. Substance Abuse Therapeutics Market to 2018-Market Overview

  • 3.1. Introduction
  • 3.2. Revenue Forecasts for Substance Abuse Therapeutics Market
    • 3.2.1. Revenue
    • 3.2.2. Annual Cost of Treatment
  • 3.3. Treatment Usage Patterns
    • 3.3.1. Diseased Population
    • 3.3.2. Diagnosed Population
    • 3.3.3. Prescription Population
  • 3.4. Drivers and Barriers for Substance Abuse Therapeutics Market
    • 3.4.1. Drivers
    • 3.4.2. Barriers

4. Substance Abuse Therapeutics Market to 2018-Geographical Landscape

  • 4.1. The US
    • 4.1.1. Revenue
    • 4.1.2. Annual Cost of Treatment
    • 4.1.3. Treatment Usage Patterns
    • 4.1.4. Diagnosed Population
    • 4.1.5. Prescription Population
  • 4.2. Top Five Countries of Europe
    • 4.2.1. Revenue
    • 4.2.2. Annual Cost of Treatment
    • 4.2.3. Treatment Usage Patterns
  • 4.3. Japan
    • 4.3.1. Revenue
    • 4.3.2. Annual Cost of Treatment
    • 4.3.3. Treatment Usage Patterns

5. Substance Abuse Therapeutics Market to 2018-Nicotine Addiction Therapeutics Market

  • 5.1. Introduction
    • 5.1.1. Treatment Flow Algorithm
    • 5.1.2. Opportunities/Unmet Needs
    • 5.1.3. Revenue
    • 5.1.4. Annual Cost of Treatment
    • 5.1.5. Treatment Usage Patterns
    • 5.1.6. Drivers and Barriers for the Nicotine Addiction Market
    • 5.1.7. Drivers
    • 5.1.8. Barriers
  • 5.2. Marketed Products
    • 5.2.1. Chantix (varenicline)
    • 5.2.2. Zyban (buproprion hydrochloride)
    • 5.2.3. Nicotine Replacement Therapies

6. Substance Abuse Therapeutics Market to 2018-Alcohol Dependence Therapeutics Market

  • 6.1. Introduction
    • 6.1.1. Treatment Flow
    • 6.1.2. Opportunities/Unmet Needs
    • 6.1.3. Revenue
    • 6.1.4. Annual Cost of Treatment
    • 6.1.5. Treatment Usage Patterns
  • 6.2. Drivers and Barriers for Alcohol Dependence Therapeutic Market
    • 6.2.1. Drivers
    • 6.2.2. Barriers
  • 6.3. Marketed Products
    • 6.3.1. Detoxification treatment options
    • 6.3.2. Campral (acamprosate calcium)
    • 6.3.3. Antabuse (disulfurum)
    • 6.3.4. Vivitrol (naltrexone)

7. Substance Abuse Therapeutics Market to 2018-Drug Abuse Therapeutics Market

  • 7.1. Introduction
    • 7.1.1. Opioid Abuse
    • 7.1.2. Cocaine Abuse
    • 7.1.3. Treatment Flow Algorithm
    • 7.1.4. Opportunities/Unmet Needs
  • 7.2. Revenues
    • 7.2.1. Annual Cost of Therapy
    • 7.2.2. Treatment Usage Patterns
  • 7.3. Drivers and Barriers for Drug Abuse
    • 7.3.1. Drivers
    • 7.3.2. Barriers
  • 7.4. Marketed Drugs-Opioid Abuse
    • 7.4.1. Methadone
    • 7.4.2. Suboxone (buprenorphine and naloxone)
    • 7.4.3. Buprenorphine Hydrochloride
    • 7.4.4. Vivitrol (naltrexone)
  • 7.5. Marketed Products-Cocaine Abuse
    • 7.5.1. Overview
    • 7.5.2. Sabril (vigabatrin)
    • 7.5.3. Fluoxetine
    • 7.5.4. Disulfiram (Antabuse)
    • 7.5.5. Naltrexone
    • 7.5.6. Topiramate
    • 7.5.7. Amantadine
    • 7.5.8. Baclofen
    • 7.5.9. Modafinil

8. Substance Abuse Therapeutics Market to 2018-Product Pipeline Analysis

  • 8.1. R&D Pipeline-Nicotine Addiction Therapeutics Market
    • 8.1.1. Pre-clinical and Discovery Phase
    • 8.1.2. Phase I
    • 8.1.3. Phase II
    • 8.1.4. Promising Pipeline Molecules
  • 8.2. R&D Pipeline-Alcohol Dependence Therapeutics Market
    • 8.2.1. Pre-clinical and Discovery Phase
    • 8.2.2. Phase I
    • 8.2.3. Phase II
    • 8.2.4. NDA Filed
    • 8.2.5. Promising Molecules in the Pipeline
    • 8.2.6. NS11
  • 8.3. R&D Pipeline-Drug Abuse Therapeutics Market
    • 8.3.1. Pre-clinical and Discovery Phase
    • 8.3.2. Phase I
    • 8.3.3. Phase II
    • 8.3.4. Phase III
    • 8.3.5. Promising Molecules in the Pipeline

9. Substance Abuse Therapeutics Market to 2018-Competitive Landscape

  • 9.1. GlaxoSmithKline
    • 9.1.1. Overview
    • 9.1.2. Major Products in the Substance Abuse Therapeutics Market
    • 9.1.3. SWOT Analysis
  • 9.2. Pfizer
    • 9.2.1. Overview
    • 9.2.2. Major Products in the Substance Abuse Therapeutics Market
    • 9.2.3. SWOT Analysis
  • 9.3. Alkermes
    • 9.3.1. Overview
    • 9.3.2. Major Products in the Substance Abuse Therapeutics Market
    • 9.3.3. SWOT Analysis
  • 9.4. Forest Laboratories, Inc.
    • 9.4.1. Overview
    • 9.4.2. Major Products in the Substance Abuse Therapeutics Market
    • 9.4.3. SWOT Analysis
  • 9.5. Teva Pharmaceuticals
    • 9.5.1. Overview
    • 9.5.2. Major Products in the Substance Abuse Therapeutics Market
    • 9.5.3. SWOT Analysis
  • 9.6. Reckitt Benckiser Pharmaceuticals
    • 9.6.1. Overview
    • 9.6.2. Major Products in the Substance Abuse Therapeutics Market
    • 9.6.3. SWOT Analysis

10. Substance Abuse Therapeutics Market to 2018-Strategic Consolidations

  • 10.1. Mergers and Acquisitions (M&A)
    • 10.1.1. Deals by Year
    • 10.1.2. Deals by Geography
    • 10.1.3. Major Mergers and Acquisitions, 2007-2012
  • 10.2. Licensing Agreements
    • 10.2.1. Deals by Year
    • 10.2.2. Deals by Geography
    • 10.2.3. Major Licensing and Co-Development Agreements, 2007-2012

11. Substance Abuse Therapeutics Market to 2018-Appendix

  • 11.1. Market Definitions
  • 11.2. Abbreviations
  • 11.3. Bibliography
  • 11.4. Research Methodology
    • 11.4.1. Coverage
    • 11.4.2. Secondary Research
    • 11.4.3. Primary Research
  • 11.5. Therapeutic Landscape
    • 11.5.1. Epidemiology-based Forecasting
    • 11.5.2. Market Size by Geography
  • 11.6. Geographical Landscape
  • 11.7. Pipeline Analysis
  • 11.8. Competitive Landscape
    • 11.8.1. Expert Panel Validation
  • 11.9. Contact Us
  • 11.10. Disclaimer

List of Tables

  • Table 1: Substance Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2011
  • Table 2: Substance Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
  • Table 3: Substance Abuse Therapeutics Market, Global, ACT ($), 2004-2011
  • Table 4: Substance Abuse Therapeutics Market, Global, ACT ($), 2011-2018
  • Table 5: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2004-2011
  • Table 6: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2011-2018
  • Table 7: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011
  • Table 8: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018
  • Table 9: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2011
  • Table 10: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2011-2018
  • Table 11: Substance Abuse Therapeutics Market, The US, Revenue ($bn), 2004-2011
  • Table 12: Substance Abuse Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018
  • Table 13: Substance Abuse Therapeutics Market, The US, ACT ($), 2004-2011
  • Table 14: Substance Abuse Therapeutics Market, The US, ACT ($), 2011-2018
  • Table 15: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2004-2011
  • Table 16: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2011-2018
  • Table 17: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2004-2011
  • Table 18: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2011-2018
  • Table 19: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2004-2011
  • Table 20: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2011-2018
  • Table 21: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011
  • Table 22: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018
  • Table 23: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2004-2011
  • Table 24: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2011-2018
  • Table 25: Substance Abuse Therapeutics Market, Top Five Countries of Europe Diseased Population (millions), 2004-2011
  • Table 26: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diseased Population (millions), 2011-2018
  • Table 27: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2004-2011
  • Table 28: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2011-2018
  • Table 29: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2004-2011
  • Table 30: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2011-2018
  • Table 31: Substance Abuse Therapeutics Market, Japan, Revenue ($m), 2004-2011
  • Table 32: Substance Abuse Therapeutics Market, Japan, Revenue Forecasts ($m), 2011-2018
  • Table 33: Substance Abuse Therapeutics Market, Japan, ACT ($), 2004-2011
  • Table 34: Substance Abuse Therapeutics Market, Japan, ACT ($), 2011-2018
  • Table 35: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions), 2004-2011
  • Table 36: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions, 2011-2018
  • Table 37: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2004-2011
  • Table 38: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2011-2018
  • Table 39: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2004-2011
  • Table 40: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2011-2018
  • Table 41: Nicotine Addiction Therapeutics Market, Global, Revenue ($bn), 2004-2011
  • Table 42: Nicotine Addiction Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
  • Table 43: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2004-2011
  • Table 44: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2011-2018
  • Table 45: Nicotine Addiction Market, Global, Diseased Population (millions), 2004-2011
  • Table 46: Nicotine Addiction Therapeutics Market, Global, Diseased Population (millions), 2011-2018
  • Table 47: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011
  • Table 48: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018
  • Table 49: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2004-2011
  • Table 50: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2011-2018
  • Table 51: Alcohol Dependence Therapeutics Market, Global, Revenue ($m), 2004-2011
  • Table 52: Alcohol Dependence Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 53: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2004-2011
  • Table 54: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2011-2018
  • Table 55: Alcohol Dependence Therapeutic Market, Global, Diseased Population (millions), 2004-2011
  • Table 56: Alcohol Dependence Therapeutic Market, Global, Diseased Population (millions), 2011-2018
  • Table 57: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011
  • Table 58: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018
  • Table 59: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000'), 2004-2011
  • Table 60: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000'), 2011-2018
  • Table 61: Drug Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2011
  • Table 62: Drug Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
  • Table 63: Drug Abuse Therapeutics Market, Global, Average ACT ($), 2004-2011
  • Table 64: Drug Abuse Therapeutics Market, Global, Average ACT ($), 2011-2018
  • Table 65: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2004-2011
  • Table 66: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2011-2018
  • Table 67: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011
  • Table 68: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018
  • Table 69: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2011
  • Table 70: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2011-2018
  • Table 71: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2011
  • Table 72: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Phase I, 2011
  • Table 73: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Phase II, 2011
  • Table 74: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2011
  • Table 75: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase I, 2011
  • Table 76: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase II, 2011
  • Table 77: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in NDA Filed, 2011
  • Table 78: Drug Abuse Therapeutics Market, Global, Pre-clinical, 2011
  • Table 79: Drug Abuse Therapeutics Market, Global, Phase I, 2011
  • Table 80: Drug Abuse Therapeutics Market, Global, Phase II, 2011
  • Table 81: Drug Abuse Therapeutics Market, Global, Phase III, 2011

List of Figures

  • Figure 1: Substance Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018
  • Figure 2: Substance Abuse Therapeutics Market, Global, ACT ($), 2004-2018
  • Figure 3: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2004-2018
  • Figure 4: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018
  • Figure 5: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2018
  • Figure 6: Substance Abuse Therapeutics Market, Drivers and Barriers, 2011
  • Figure 7: Substance Abuse Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018
  • Figure 8: Substance Abuse Therapeutics Market, The US, ACT ($), 2004-2018
  • Figure 9: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2004-2018
  • Figure 10: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2004-2018
  • Figure 11: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2004-2018
  • Figure 12: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2004-2018
  • Figure 13: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2004-2018
  • Figure 14: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diseased Population (millions), 2004-2018
  • Figure 15: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2004-2018
  • Figure 16: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2004-2018
  • Figure 17: Substance Abuse Therapeutics Market, Japan, Revenue Forecasts ($m), 2004-2018
  • Figure 18: Substance Abuse Therapeutics Market, Japan, ACT ($), 2004-2018
  • Figure 19: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions), 2004-2018
  • Figure 20: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2004-2018
  • Figure 21: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2004-2018
  • Figure 22: Nicotine Addiction Therapeutics Market, Treatment Flow Algorithm
  • Figure 23: Nicotine Addiction Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018
  • Figure 24: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2004-2018
  • Figure 25: Nicotine Addiction Therapeutics Market, Global, Diseased Population (millions), 2004-2018
  • Figure 26: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018
  • Figure 27: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2004-2018
  • Figure 28: Nicotine Addiction Therapeutics Market, Global, Drivers and Barriers, 2011
  • Figure 29: Alcohol Dependence Therapeutics Market, Treatment Flow Algorithm
  • Figure 30: Alcohol Dependence Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018
  • Figure 31: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2004-2018
  • Figure 32: Alcohol Dependence Therapeutics Market, Global, Diseased Population (millions), 2004-2018
  • Figure 33: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018
  • Figure 34: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000'), 2004-2018
  • Figure 35: Alcohol Dependence Therapeutics Market, Global, Drivers and Barriers, 2011
  • Figure 36: Drug Abuse Therapeutics Market, Treatment Flow Algorithm
  • Figure 37: Drug Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2018
  • Figure 38: Drug Abuse Therapeutics Market, Global, ACT ($), 2004-2018
  • Figure 39: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2004-2018
  • Figure 40: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018
  • Figure 41: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2018
  • Figure 42: Drug Abuse Therapeutics Market, Global, Drivers and Barriers, 2011
  • Figure 43: Substance Abuse Therapeutics Market, SWOT Analysis, GSK, 2011
  • Figure 44: Substance Abuse Therapeutics Market, SWOT Analysis, Pfizer, 2011
  • Figure 45: Substance Abuse Therapeutics Market, SWOT Analysis, Alkermes, 2011
  • Figure 46: Substance Abuse Therapeutics Market, SWOT Analysis, Forest Laboratories Inc., 2011
  • Figure 47: Substance Abuse Therapeutics Market, SWOT Analysis, Teva Pharmaceutical, 2011
  • Figure 48: Substance Abuse Therapeutics Market, SWOT Analysis, Reckitt Benckiser, 2011
  • Figure 49: Substance Abuse Therapeutics Market, Global, Major M&A Deals By Year, 2007-2012
  • Figure 50: Substance Abuse Therapeutics Market, Global, Major M&A Deals By Geography, 2007-2012
  • Figure 51: Substance Abuse Therapeutics Market, Global, R&D Licensing Deals By Year, 2007-2012
  • Figure 52: Substance Abuse Therapeutics Market, Global, Major R&D Licensing Deals By Geography, 2007-2012
  • Figure 53: GBI Research Market Forecasting Model
Back to Top